Fadi Alkhatib, DO
Allergy & Immunology · West Des Moines, IANPI 1972869717
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Genentech USA, Inc. at 40.7% of the total. Among allergy & immunology clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $33.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$6K
- AstraZeneca$3K
- GSK$1K
- Sanofi$815
- Amgen$813
- Regeneron Healthcare Solutions, Inc.$416
- plus $3K from 29 others
What the payments were for
- Consulting fees$4,96032%
- Speaking & faculty fees$5003%
- Travel & lodging$7505%
- Food & beverage$9,01658%
- Education$3392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 46 | $6,332 |
| AstraZeneca | 99 | $2,958 |
| GSK | 74 | $1,097 |
| Sanofi | 53 | $815 |
| Amgen(2 entities) | 38 | $813 |
| Regeneron Healthcare Solutions, Inc. | 20 | $416 |
| Galderma Laboratories, L.p. | 16 | $410 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $353 |
| Pharming Healthcare, Inc. | 13 | $310 |
| Boehringer Ingelheim | 8 | $283 |
| Pfizer | 13 | $238 |
| CSL Behring | 9 | $191 |
| Biocryst US Sales Co., LLC | 10 | $188 |
| Alk-abello, Inc | 8 | $148 |
| Sanofi-aventis U.S. LLC | 2 | $121 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $117 |
| Novartis | 7 | $117 |
| Optinose US, Inc. | 5 | $96 |
| Grifols USA, LLC | 4 | $68 |
| Blueprint Medicines Corporation | 3 | $66 |
| Aimmune Therapeutics, Inc. | 2 | $54 |
| Kaleo, Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Incyte Corporation | 2 | $43 |
| Phadia US Inc. | 2 | $42 |
| Ionis Pharmaceuticals, Inc. | 2 | $40 |
| Mylan Specialty L.p. | 2 | $27 |
| Tactile Systems Technology Inc | 1 | $19 |
| LEO Pharma Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $17 |
| Covis Pharma GmbH | 1 | $16 |
| Verona Pharma, Inc. | 1 | $14 |
| Organon | 1 | $13 |
| USWM, LLC | 1 | $13 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,564 in reported general payments places this provider in the 95th percentile of 32 allergy & immunology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $35,778 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $11,510 |
| Epinephrine | 43 | $8,159 |
| Spiriva RespimatTiotropium Bromide | 11 | $6,773 |
| DuleraMometasone/Formoterol | 20 | $6,679 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $5,732 |
| Arnuity ElliptaFluticasone Furoate | 24 | $5,376 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $4,063 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $3,825 |
| Azelastine Hcl | 96 | $3,132 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $2,747 |
| Montelukast Sodium | 155 | $1,572 |
| Fluticasone Propionate | 121 | $1,485 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,406 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,097 | $52,66487 claims |
| Boehringer IngelheimSpiriva Respimat | $283 | $6,77311 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $49 | $5,73214 claims |
| AstraZenecaSymbicort | $2,958 | $2,74712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 32 allergy & immunology providers in Iowa.
Other allergy & immunology in West Des Moines
- Vuong NayimaWest Des Moines$34K
- Ravinder AgarwalWest Des Moines$2K
- Ahmad AlshashWest Des Moines$872
- Jennifer PettsWest Des Moines$163
- Daniel HamilosMason City$11K
- Lyla SchweigerCedar Rapids$6K
- Edward NassifAmes$5K
- Holly BrownCedar Rapids$4K
- Whitney MolisDes Moines$4K
- Safia NawazDes Moines$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.